Selected research
Market Structure
Global Antisense and RNAi Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Antisense and RNAi Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Antisense and RNAi Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Antisense and RNAi Therapeutics include Roche, Tekmira Pharmaceuticals, Sirnaomics, Silence Therapeutics, Santaris, Isis Pharmaceuticals, Arbutus Biopharma, Antisense Therapeutics and Alnylam Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Antisense and RNAi Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Antisense and RNAi Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Antisense and RNAi Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Antisense and RNAi Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Antisense and RNAi Therapeutics Segment by Company
Roche
Tekmira Pharmaceuticals
Sirnaomics
Silence Therapeutics
Santaris
Isis Pharmaceuticals
Arbutus Biopharma
Antisense Therapeutics
Alnylam Pharmaceuticals
Antisense and RNAi Therapeutics Segment by Type
RNA Interference
Antisense RNA
Antisense and RNAi Therapeutics Segment by Application
Hospital
Clinic
Antisense and RNAi Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense and RNAi Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antisense and RNAi Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense and RNAi Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Antisense and RNAi Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense and RNAi Therapeutics industry.
Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense and RNAi Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Interference
- Antisense RNA
Applications
- Hospital
- Clinic
Companies covered
- Roche
- Tekmira Pharmaceuticals
- Sirnaomics
- Silence Therapeutics
- Santaris
- Isis Pharmaceuticals
- Arbutus Biopharma
- Antisense Therapeutics
- Alnylam Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 RNA Interference
- 1.2.3 Antisense RNA
- 1.3 Market Analysis by Application
- 1.3.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.4 Global Market Growth Prospects
- 1.5 Global Antisense and RNAi Therapeutics Growth Trends by Region
- 1.5.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Antisense and RNAi Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Antisense and RNAi Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Antisense and RNAi Therapeutics Market Dynamics
- 2.1 Antisense and RNAi Therapeutics Industry Trends
- 2.2 Antisense and RNAi Therapeutics Industry Drivers
- 2.3 Antisense and RNAi Therapeutics Industry Opportunities and Challenges
- 2.4 Antisense and RNAi Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Antisense and RNAi Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Antisense and RNAi Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Antisense and RNAi Therapeutics Key Company Head office and Area Served
- 3.4 Global Antisense and RNAi Therapeutics Company, Product Type & Application
- 3.5 Global Antisense and RNAi Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Antisense and RNAi Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Antisense and RNAi Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Antisense and RNAi Therapeutics Tier 1, Tier 2, and Tier 3
4 Antisense and RNAi Therapeutics Market by Type
- 4.1 Global Antisense and RNAi Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Antisense and RNAi Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Antisense and RNAi Therapeutics Market Size Share by Type (2021-2032)
5 Antisense and RNAi Therapeutics Market by Application
- 5.1 Global Antisense and RNAi Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Antisense and RNAi Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Antisense and RNAi Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Roche
- 6.1.1 Roche Company Information
- 6.1.2 Roche Business Overview
- 6.1.3 Roche Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Roche Antisense and RNAi Therapeutics Product Portfolio
- 6.1.5 Roche Recent Developments
- 6.2 Tekmira Pharmaceuticals
- 6.2.1 Tekmira Pharmaceuticals Company Information
- 6.2.2 Tekmira Pharmaceuticals Business Overview
- 6.2.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 6.2.5 Tekmira Pharmaceuticals Recent Developments
- 6.3 Sirnaomics
- 6.3.1 Sirnaomics Company Information
- 6.3.2 Sirnaomics Business Overview
- 6.3.3 Sirnaomics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sirnaomics Antisense and RNAi Therapeutics Product Portfolio
- 6.3.5 Sirnaomics Recent Developments
- 6.4 Silence Therapeutics
- 6.4.1 Silence Therapeutics Company Information
- 6.4.2 Silence Therapeutics Business Overview
- 6.4.3 Silence Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Silence Therapeutics Antisense and RNAi Therapeutics Product Portfolio
- 6.4.5 Silence Therapeutics Recent Developments
- 6.5 Santaris
- 6.5.1 Santaris Company Information
- 6.5.2 Santaris Business Overview
- 6.5.3 Santaris Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Santaris Antisense and RNAi Therapeutics Product Portfolio
- 6.5.5 Santaris Recent Developments
- 6.6 Isis Pharmaceuticals
- 6.6.1 Isis Pharmaceuticals Company Information
- 6.6.2 Isis Pharmaceuticals Business Overview
- 6.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 6.6.5 Isis Pharmaceuticals Recent Developments
- 6.7 Arbutus Biopharma
- 6.7.1 Arbutus Biopharma Company Information
- 6.7.2 Arbutus Biopharma Business Overview
- 6.7.3 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Arbutus Biopharma Antisense and RNAi Therapeutics Product Portfolio
- 6.7.5 Arbutus Biopharma Recent Developments
- 6.8 Antisense Therapeutics
- 6.8.1 Antisense Therapeutics Company Information
- 6.8.2 Antisense Therapeutics Business Overview
- 6.8.3 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Antisense Therapeutics Antisense and RNAi Therapeutics Product Portfolio
- 6.8.5 Antisense Therapeutics Recent Developments
- 6.9 Alnylam Pharmaceuticals
- 6.9.1 Alnylam Pharmaceuticals Company Information
- 6.9.2 Alnylam Pharmaceuticals Business Overview
- 6.9.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product Portfolio
- 6.9.5 Alnylam Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Antisense and RNAi Therapeutics Market Size (2021-2032)
- 7.2 North America Antisense and RNAi Therapeutics Market Size by Type
- 7.2.1 North America Antisense and RNAi Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Antisense and RNAi Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Antisense and RNAi Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Antisense and RNAi Therapeutics Market Size by Application
- 7.3.1 North America Antisense and RNAi Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Antisense and RNAi Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Antisense and RNAi Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Antisense and RNAi Therapeutics Market Size by Country
- 7.4.1 North America Antisense and RNAi Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Antisense and RNAi Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Antisense and RNAi Therapeutics Market Size (2021-2032)
- 8.2 Europe Antisense and RNAi Therapeutics Market Size by Type
- 8.2.1 Europe Antisense and RNAi Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Antisense and RNAi Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Antisense and RNAi Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Antisense and RNAi Therapeutics Market Size by Application
- 8.3.1 Europe Antisense and RNAi Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Antisense and RNAi Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Antisense and RNAi Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Antisense and RNAi Therapeutics Market Size by Country
- 8.4.1 Europe Antisense and RNAi Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Antisense and RNAi Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Antisense and RNAi Therapeutics Market Size (2021-2032)
- 9.2 China Antisense and RNAi Therapeutics Market Size by Type
- 9.2.1 China Antisense and RNAi Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Antisense and RNAi Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Antisense and RNAi Therapeutics Market Share by Type (2021-2032)
- 9.3 China Antisense and RNAi Therapeutics Market Size by Application
- 9.3.1 China Antisense and RNAi Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Antisense and RNAi Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Antisense and RNAi Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Antisense and RNAi Therapeutics Market Size (2021-2032)
- 10.2 Asia Antisense and RNAi Therapeutics Market Size by Type
- 10.2.1 Asia Antisense and RNAi Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Antisense and RNAi Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Antisense and RNAi Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Antisense and RNAi Therapeutics Market Size by Application
- 10.3.1 Asia Antisense and RNAi Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Antisense and RNAi Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Antisense and RNAi Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Antisense and RNAi Therapeutics Market Size by Country
- 10.4.1 Asia Antisense and RNAi Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Antisense and RNAi Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Antisense and RNAi Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst